UCSD

Ramsdell
Dr. Joe Ramsdell
Director

Ferguson
Paul Ferguson
Executive Director

COPD Studies

Forest ROF-MD-07: This is a phase 4 study that targets patients 40 years of age and older with severe to very severe COPD with a history of at least two moderate or severe exacerbations within 12 months prior to screening. The purpose of this study is to investigate how well roflumilast (marketed as Daliresp® in the United States) reduces the frequency of exacerbations in people with severe COPD, when used with a combination of two medications at an unchanged dose, known as a long-acting β2 agonist (LABA) and an inhaled corticosteroid (ICS). There are two LABA/ICS combination medications, Advair® (at a 250/50 µg dose) and Symbicort® (at a 160/4.5 µg dose). Both are currently FDA-approved in the U.S. and marketed worldwide (approved by health authorities in many countries for use in humans) for the treatment of COPD. There will also be a placebo (contains no roflumilast or any other active ingredient) used in this study. Some people in this study will get placebo along with Advair® or Symbicort® to compare the effects of roflumilast with Advair® or Symbicort®. The total time in the study, from screening (first study visit) to the end of the study, will be approximately fifty eight (58) weeks. There will be up to 8 total visits to the study site. Please click on the consent form to see if you might participate.(Click For Consent)
COPD Gene:The University of California, San Diego Clinical Trials & Airways Research Center is participating in a national study to find out more about genetic causes of COPD.
GlaxoSmithKline HZC113782 Study: This study is a clinical outcomes study to compare the effect of fluticasone furoate/vilanterol inhalation powder 100/25mcg with placebo on survival in subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at risk for cardiovascular disease (12-months).
GlaxoSmithKline DB2113361 Study: A 24-Week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GSK573719/GW642444 inhalation powder and the individual components delivered once-daily via a novel dry powder inhaler in subjects with Chronic Obstructive Pulmonary Disease.(Closed)
NOVARTIS CQVA149A2304 STUDY: A 64-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium (18 μg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD). (Closed)
Forest LAC-MD-31 Study: A long-term (52-week), randomized, study of the safety and tolerability of a fixed-dose combination of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe, stable Chronic Obstructive Pulmonary Disease (COPD).(Closed)

Back to Top


Click Here to Stop Smoking